There has been considerable external validation of bisantrene...

There has been considerable external validation of bisantrene and Race. Everyone seems to have forgotten the Astex/Otsuka collaboration, both the past EMD AML program and the proposed investigator AML trial which will also be another collaboration with Astex. They don't share their drug unless they think the other drug it is going to be partnered with is valuable. Probably, the biggest external validation is the Austalia investigator wanting to do the AML trial - they are only doing this because they know the potential of bisantrene.

The reason we don't have insto investors on the registry (other than Merchant) is we have not been raising capital. Insto investors just don't buy new positions in speculative biotechs on market, they only buy into a stock via a capital raise and we haven't done a conventional CR since 2020. Everyone has probably forgotten, but that raise was to sophisticated biotech investors. They sold out out at 75c right before the run to $4.23.

We can go out tomorrow and get insto and pharma investors, but I suspect none of you would like the terms. Be careful for what you wish for.

All the projects including the development of RC220 remain on track and are progressing well. I certainly understand the scepticism from shareholders after all the drama of 2023, but things really are different in 2024.

Oh I should add to not forget the possibility of a good surprise - Race has had plenty is the past and I am sure there will be more in the future.